KR20230146593A - Parp7 억제제에 대한 투여량 레지멘 - Google Patents

Parp7 억제제에 대한 투여량 레지멘 Download PDF

Info

Publication number
KR20230146593A
KR20230146593A KR1020237031337A KR20237031337A KR20230146593A KR 20230146593 A KR20230146593 A KR 20230146593A KR 1020237031337 A KR1020237031337 A KR 1020237031337A KR 20237031337 A KR20237031337 A KR 20237031337A KR 20230146593 A KR20230146593 A KR 20230146593A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237031337A
Other languages
English (en)
Korean (ko)
Inventor
멜리사 마리 바스바인더
루카스 제이. 우틀리
비비안나 보존
케빈 웨인 쿤츠
수다 파라수라만
윌리엄 맥쿨로츠
놀란 우드
Original Assignee
리본 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리본 테라퓨틱스 인코포레이티드 filed Critical 리본 테라퓨틱스 인코포레이티드
Publication of KR20230146593A publication Critical patent/KR20230146593A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237031337A 2021-02-16 2022-02-15 Parp7 억제제에 대한 투여량 레지멘 Pending KR20230146593A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163149901P 2021-02-16 2021-02-16
US63/149,901 2021-02-16
US202163275163P 2021-11-03 2021-11-03
US63/275,163 2021-11-03
PCT/US2022/016403 WO2022177877A1 (en) 2021-02-16 2022-02-15 Dosage regimens for parp7 inhibitors

Publications (1)

Publication Number Publication Date
KR20230146593A true KR20230146593A (ko) 2023-10-19

Family

ID=80449181

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237031337A Pending KR20230146593A (ko) 2021-02-16 2022-02-15 Parp7 억제제에 대한 투여량 레지멘

Country Status (6)

Country Link
US (3) US20220265654A1 (https=)
EP (1) EP4294399A1 (https=)
JP (1) JP2024506684A (https=)
KR (1) KR20230146593A (https=)
TW (1) TW202245777A (https=)
WO (1) WO2022177877A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202245777A (zh) * 2021-02-16 2022-12-01 美商律幫治療股份有限公司 Parp7抑制劑之給藥方案
EP4570806A1 (en) * 2022-08-09 2025-06-18 Kangbaida (Sichuan) Biotechnology Co., Ltd. Composition of piperazine compound and pd-1 inhibitor or pd-l1 inhibitor and use thereof in treating tumors
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7273791B2 (ja) * 2017-04-10 2023-05-15 シエラ オンコロジー， インコーポレイテッド 腫瘍成長を阻害するＣＨＫ１（ＳＲＡ７３７）／ＰＡＲＰｉ組み合わせ方法
JP2020525427A (ja) * 2017-06-21 2020-08-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置するための方法
FI3788040T3 (fi) * 2018-04-30 2023-06-13 Ribon Therapeutics Inc Pyridatsinoneja parp7-inhibiittoreina
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
TW202245777A (zh) * 2021-02-16 2022-12-01 美商律幫治療股份有限公司 Parp7抑制劑之給藥方案

Also Published As

Publication number Publication date
US20240325391A1 (en) 2024-10-03
JP2024506684A (ja) 2024-02-14
US20250064803A1 (en) 2025-02-27
EP4294399A1 (en) 2023-12-27
WO2022177877A1 (en) 2022-08-25
TW202245777A (zh) 2022-12-01
US20220265654A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
US20250064803A1 (en) Dosage regimens for parp7 inhibitors
JP7482180B2 (ja) 癌のための併用療法
US20220387618A1 (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
TW202523284A (zh) 用於治療子宮內膜癌的方法、組成物和組合
EP4149455A1 (en) Atr inhibitors for the treatment of cancer
CN114173776A (zh) 用于转移性或晚期乳腺癌患者的6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸
JP7579781B2 (ja) Ｃｄｃ７阻害剤を含む癌の治療方法
CN112566660A (zh) 具有braf突变的癌症的组合疗法
JP2024012649A (ja) Ｃｈｋ１阻害剤を含む癌の治療方法
JP2025156353A (ja) 免疫調節を使用したがんの治療のための新規アプローチ
EP4168008B1 (en) A combination of belzutifan and lenvatinib for use in treating cancer
US20240173293A1 (en) Treatment of Breast Cancer with Amcenestrant and Palbociclib
TWI775333B (zh) 治療癌症之方法
CN117177753A (zh) Parp7抑制剂的剂量方案
US20250268900A1 (en) Combination therapy using a substituted pyrimidin-4(3h)-one and nivolumab as well as its use in the treatment of cancer
Yang et al. HS-10296–a novel third generation EGFR tyrosine kinase inhibitor: results of the first-in-human phase 1 trial in patients with previously treated EGFR mutant advanced non-small-cell lung cancer
TW202535383A (zh) 治療方法
KR20260053359A (ko) 자궁내막암 치료를 위한 항-pd-l1 항체와 하나 이상의 화학요법제의 조합
IL305624A (en) Methods for treating non-Hodgkin's lymphoma using 2-(2,6-deoxypyridin-3YL)-4-(2-FLUORO-4-((3-morpholinoazetidine-1-YL)methyl)benzyl)amino)isoindoline-1, - DIONEN
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
Netherlands et al. A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230913

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250214

Comment text: Request for Examination of Application